We’re proud to announce Nicolo Zarotti as a 2025 HDBuzz Prize winner! A new case study shows Acceptance & Commitment Therapy ...

Prilenia has publicly shared the data from the PROOF-HD study over the course of the last few years, at HD conferences and other research events. This recent paper reiterates the main points – overall ...

We’re proud to announce Eva Woods as a 2025 HDBuzz Prize winner! Scientists spotted small brainwave changes in people with HD before symptoms begin. These early electrical “whispers” of HD could help ...

As we wave goodbye to 2024, the HDBuzz team reflects on a year marked by significant progress, challenges, and hope. From breakthroughs at the lab bench, advancements in drug development, and both ...

People who develop Huntington’s disease (HD) are born with the genetic change that causes the disease. So why does it take decades, usually around 40 to 50 years, for the symptoms of the disease to ...

While HD primarily affects the brain, people with HD have subtle changes to their nervous system that can also affect heart rate and blood pressure. The scientists who worked on this paper had ...

CRISPR is short for “clustered regularly interspaced short palindromic repeats” – quite a mouthful! That’s essentially just science-speak for short strings of DNA letters that break up repeating parts ...

Hello from Palm Springs! The HDBuzz team are here and ready to report on all of the exciting science that we are going to hear over the next 3 days from HD experts who have travelled from all over the ...

A new CRISPR-based technology, called RIDE, is a leap forward for this trail-blazing technology. With the precision of a scalpel sharp enough to rewrite the very code of life, researchers have used it ...

Last month, we relayed positive news from uniQure’s trial testing AMT-130, a gene therapy delivered via brain surgery to lower huntingtin (HTT). Data released by uniQure in June suggested AMT-130 was ...

For those who were following the live tweets from HDBuzz about the CHDI HD Therapeutics Conference or tuned in to the HDSA Convention, we may have caught your attention with the new HD staging system.

Developed by uniQure, AMT-130 is the first gene therapy for HD. Like many of the other therapies being tested in the clinic right now, it aims to reduce the levels of the HD protein, huntingtin, in ...